TG Therapeutics Inc (TGTX)
Price $64.51 · -0.08% today · $9.8B market cap.
biotech_pharma
Simulated history. Equities don't yet have ingested OHLCV, so the price chart and technical indicators below are illustrative (deterministic, labelled) — not real market history.
Price & Performance
$64.51 -2.0% over 1Y
Simulated history — illustrative, not real market data.
Today
-0.08%
1 week
+1.78%
1 month
+5.44%
1 year
+108.37%
Technical Analysis
RSI (14)
42.70
MACD
-2.00
MACD signal
-1.81
MACD hist
-0.19
SMA 20
67.04
SMA 50
69.72
EMA 20
65.92
ATR (14)
2.01
Support
60.95
Resistance
75.17
Bollinger upper
74.76
Bollinger lower
59.33
- ▹ RSI 43 — neutral
- ▹ MACD below signal (bearish)
- ▹ Price below moving averages
Indicators describe past price action — they do not predict future direction.
Fundamental Analysis
P/E ratio
22.09
Return on equity
72.30%
EBITDA
n/a
EPS (TTM)
2.75
Net debt
n/a
Net margin
55.22%
Gross margin
82.37%
Current ratio
4.27
Debt / Equity
1.23
Dividend yield
n/a
Operating margin
15.91%
Revenue growth (YoY)
76.08%
Risk Assessment
Ann. volatility
27.7%
Max drawdown
20.1%
Liquidity
Adequate market capitalization
Leverage
Debt/equity 1.2 (manageable)
Valuation
P/E 22×
Earnings
Earnings dates are not tracked in this release.
Concentration
Single-name equity — no diversification within the position.
Estimated annualized volatility 28% with a maximum drawdown of 20% over the available window.
Investment Thesis (generated summary)
TG Therapeutics Inc (TGTX) screens constructively on the current data, with an opportunity score of 73/100. The score reflects the available fundamental, technical, valuation and sentiment inputs — it is a research screen, not a forecast or a recommendation to trade.
Bullish case
- Strong net margin (55%)
- Revenue growing 76% y/y
- Reasonable P/E (22×)
Potential catalysts
- TG Therapeutics: 3 Key Takeaways for Long-Term Investors
- Stock Market Rebounds Even As Nvidia CEO Jensen Huang Resigns, Treasury Yields Jump: Weekly Review
- The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
Horizon: ~1–3 months for technical signals; 12+ months for fundamental quality.
Thesis invalidated if: Momentum reverses and price breaks below its 50-day average; Earnings or guidance disappoint relative to consensus; A sector-level drawdown outweighs stock-specific strength.
News Sentiment
Bullish 62.5%Neutral 37.5%Bearish 0%
Recent News
Yahoo2026-11-15
Yahoo2026-11-13
Yahoo2026-11-11
Disclaimer. AI-generated, informational and educational only. Not financial advice. Past performance does not indicate future results.